Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Kék Lukács Ointment (also known as Kék Kenőcs or Blue Ointment) is a topical combination therapy developed by Hungarian pharmacist Dr. Károly Lukács and associated with Lukács és Társa Gyógyszerkereskedelmi Betéti Társaság. It is primarily investigated for the treatment of deep partial thickness (second-degree) burn wounds. The formulation contains a combination of antibacterial and antifungal agents, including sulfamethoxazole (a sulfonamide antibiotic), miconazole (an imidazole antifungal), and azithromycin (a macrolide antibiotic). The ointment is designed to reduce the risk of wound superinfection and promote healing from the bottom up, aiming for smooth scar formation. It has been evaluated in a Phase II randomized controlled pilot trial in Hungary, comparing its efficacy against standard silver sulfadiazine (SSD).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Kék Lukács Ointment.